Medical cannabis – drapalin is working on a non-interventional study on cannabis therapy for adhd and is asking interested doctors to participate.
Munich – Medical cannabis has already established itself as a therapeutic option for many conditions. Nevertheless, there are still many areas of application in which numerous patients are successfully treated with cannabis, but this has so far received little attention in research. In these cases, there are many promising patient experiences, but well-founded data on medical efficacy are still scarce. This is where Drapalin Pharmaceuticals GmbH would like to start with a non-interventional study on the use of medical cannabis for ADHD in adults.
With an estimated prevalence of 5%, attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children and adolescents. However, in more than half of those affected, symptoms persist into adulthood and severely interfere with patients’ daily lives.
Since the new legal requirements regarding the use of cannabis for medical purposes came into force in 2017, some ADHD patients have already benefited from medicinal cannabis and experience a significant improvement in their quality of life as a result of this therapy. 1
DRAPALIN would like to contribute to the knowledge about the use of medicinal cannabis for ADHD by conducting an observational study (AWB). The AWB will be conducted according to the requirements of the AMG. Transparency and objectivity are important to DRAPALIN. The aim is to raise awareness of the use of medicinal cannabis in ADHD and at the same time to contribute to its effectiveness.
“Interested physicians are cordially invited to participate in this AWB. They are welcome to approach our company to be informed about the specific content of the AWB,” says Lana Korneva, co-founder and CEO of DRAPALIN. The AWB will be conducted in collaboration with an experienced contract research organization, ensuring that the results will eventually be summarized and provided to the drug regulatory authority as required by the AMG.
Participation in the AWB thus offers physicians the opportunity to actively shape the future of patient-specific therapies and contribute to the expansion of knowledge about the efficacy and possible uses of medicinal cannabis.
For information on the launch of AWB, please contact us by phone or by email at awb(@)drapalin.de without obligation.
Drapalin Pharmaceuticals GmbH
Paul-Heyse-Str. 28
80336 Munich
Phone: +49 (89) 277 801 320
E-Mail: info(@)drapalin.de
Internet: drapalin.de
Based on the materials www.apotheke-adhoc.de
